Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US6402683063
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BHCYJ1
NKTR

Nektar Therapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Nektar Therapeutics
ISIN
US6402683063
TICKER
NKTR
MIC
XNAS
REUTERS
NKTR.OQ
BLOOMBERG
NKTR US
Thu, 26.03.2026       Nektar Therapeutics

Key Dates and Disclosure Events Shareholders Need to KnowNEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Nektar Therapeutics (NASDAQ: NKTR) to contact the firm. Those who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be entitled to recover damages. Find out if you are e...
Thu, 26.03.2026       Nektar Therapeutics

NEW YORK, March 25, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclu...
Wed, 25.03.2026       Nektar Therapeutics

LOS ANGELES, March 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit....
Wed, 25.03.2026       Nektar Therapeutics

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Wed, 25.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Tue, 24.03.2026       Nektar Therapeutics

Levi & Korsinsky, LLP alerts investors in Nektar Therapeutics (NASDAQ: NKTR) of a pending securities class action. Class Period: February 26, 2025 through December 15, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500. Nektar shares fell $4.14 per share, or 7.77%...
Tue, 24.03.2026       Nektar Therapeutics

NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Tue, 24.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Tue, 24.03.2026       Nektar Therapeutics

SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies...
Mon, 23.03.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Silent Ad
Mon, 23.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Mon, 23.03.2026       Nektar Therapeutics

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Mon, 23.03.2026       Nektar Therapeutics

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Sun, 22.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Sat, 21.03.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Sat, 21.03.2026       Nektar Therapeutics

NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus...
Sat, 21.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Fri, 20.03.2026       Nektar Therapeutics

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “...
Fri, 20.03.2026       Nektar Therapeutics

SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31, 2026, in...
Fri, 20.03.2026       Nektar Therapeutics

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Silent Ad
Fri, 20.03.2026       Nektar Therapeutics

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Thu, 19.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 19, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclu...
Thu, 19.03.2026       Nektar Therapeutics

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf o...
Thu, 19.03.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Thu, 19.03.2026       Nektar Therapeutics

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, March 19, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Thu, 19.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Wed, 18.03.2026       Nektar Therapeutics

Law Offices of Howard G. Smith reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVES...
Wed, 18.03.2026       Nektar Therapeutics

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Wed, 18.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Tue, 17.03.2026       Nektar Therapeutics

Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025. YOUR OPTIONS: You may be entitled to compensation without payment of...
Tue, 17.03.2026       Nektar Therapeutics

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive...
Tue, 17.03.2026       Nektar Therapeutics

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Tue, 17.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Mon, 16.03.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Mon, 16.03.2026       Nektar Therapeutics

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). Nektar investors have until May 5, 2026 to fil...
Mon, 16.03.2026       Nektar Therapeutics

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Mon, 16.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Sun, 15.03.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Sun, 15.03.2026       Nektar Therapeutics

NEW YORK, March 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an...
Sun, 15.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Sat, 14.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Fri, 13.03.2026       Nektar Therapeutics

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). Nektar investors have until May 5, 2026 to file a lead plaintiff motion....
Fri, 13.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Thu, 12.03.2026       Nektar Therapeutics

SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable securities on December 31, 2025 were...
Thu, 12.03.2026       Nektar Therapeutics

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON N...
Thu, 12.03.2026       Nektar Therapeutics

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf...
Thu, 12.03.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Thu, 12.03.2026       Nektar Therapeutics

Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEKTAR THERAPEUTICS (NKTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTI...
Thu, 12.03.2026       Nektar Therapeutics

The Law Offices of Frank R. Cruz announces an investigation of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEKTAR THERAPEUTICS (NKTR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM...
Wed, 11.03.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...